CRISPR Therapeutics (NASDAQ:CRSP) PT Raised to $88.00
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price objective increased by Needham & Company LLC from $85.00 to $88.00 in a research note issued to investors on Monday morning, Benzinga reports. The firm currently has a buy rating on the stock. A number of other analysts have also recently weighed in on the stock. […]
More Stories
Braemar Plc Declares Dividend of GBX 4.50 (LON:BMS)
Braemar Plc (LON:BMS – Get Free Report) declared a dividend on Wednesday, November 6th,Upcoming Dividends.Co.Uk reports. Investors of record on...
First City Capital Management Inc. Trims Stock Holdings in International Business Machines Co. (NYSE:IBM)
First City Capital Management Inc. reduced its stake in International Business Machines Co. (NYSE:IBM – Free Report) by 1.1% during...
Equita Financial Network Inc. Buys Shares of 419 Vanguard Information Technology ETF (NYSEARCA:VGT)
Equita Financial Network Inc. bought a new stake in Vanguard Information Technology ETF (NYSEARCA:VGT – Free Report) during the 3rd...
First City Capital Management Inc. Sells 178 Shares of SPDR Dow Jones Industrial Average ETF Trust (NYSEARCA:DIA)
First City Capital Management Inc. reduced its position in shares of SPDR Dow Jones Industrial Average ETF Trust (NYSEARCA:DIA –...
L3Harris Technologies, Inc. (NYSE:LHX) Shares Sold by First City Capital Management Inc.
First City Capital Management Inc. cut its holdings in L3Harris Technologies, Inc. (NYSE:LHX – Free Report) by 24.0% in the...
Meeder Advisory Services Inc. Acquires 51 Shares of Public Storage (NYSE:PSA)
Meeder Advisory Services Inc. raised its stake in shares of Public Storage (NYSE:PSA – Free Report) by 1.4% during the...